N-ethylmaleimide sensitive factor (NSF) plays a critical role in the regulation of exocytosis. NSF regulates exocytosis by interacting with a complex containing SNARE molecules, hydrolyzing ATP, and disassembling the SNARE complex. We hypothesized that peptide inhibitors of NSF would decrease exocytosis. We now report the development of a novel set of peptides that block exocytosis by inhibiting NSF activity. These NSF inhibitors are fusion polypeptides composed of an 11 amino acid HIV TAT domain fused to a 22 amino acid NSF domain. These TAT-NSF fusion polypeptides cross endothelial cell membranes, inhibit NSF hydrolysis of ATP, decrease NSF disassembly of SNARE molecules, and block exocytosis of vWF. Control peptides have no effect on exocytosis. TAT-NSF inhibitors administered to mice prolong the bleeding time. Blood concentrations of these TAT-NSF peptides rapidly decrease within 5 min after injection, and then remain constant from 10 min through 60 min after injection. These TAT-NSF compounds may be useful in the treatment of a variety of diseases in which exocytosis plays a prominent role, including myocardial infarction, stroke, thrombosis, and autoimmune disorders.
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Introduction
Exocytosis plays a prominent role in cell biology. A variety of cell types respond to extracellular stimuli by releasing the contents of vesicle or granules to the external environment.
For example, depolarizing neurons trigger exocytosis of neurovesicles, releasing neurotransmitters which activate post-synaptic neurons. Adrenal chromaffin cells respond to external signals such as histamine, angiotensin II, and opioids by exocytosis of chromaffin granules containing catecholamines and other components. Endothelial cells respond to a variety of signals, including thrombin, histamine, and ATP by exocytosis of Weibel-Palade bodies (Birch et al., 1994; Datta et al., 1995; Foreman et al., 1994; Vischer et al., 1995; Vischer and Wollheim, 1997) . Weibel-Palade bodies are endothelial granules that contain von Willebrand factor (vWF), P-selectin, and interleukin-8 (IL-8) (Utgaard et al., 1998; Wagner, 1993; Wolff et al., 1998) . Since vWF causes platelet aggregation, since P-selectin promotes neutrophil adherence to vessel walls, and since IL-8 attracts and activates neutrophils, the contents of Weibel-Palade bodies can promote vascular inflammation and thrombosis.
We recently showed that endothelial exocytosis is regulated in part by the cellular machinery that regulates vesicle trafficking, including: SNAREs, NSF, Rab, Munc, and other accessory proteins (Matsushita et al., 2003) . Soluble NSF Attachment protein Receptors (SNAREs) are transmembrane proteins that regulate vesicle fusion (Ferro-Novick and Jahn, 1994) . Vesicle SNAREs (v-SNAREs) are localized to vesicle membranes, and target SNAREs (t-SNAREs) are localized to target membranes (Sollner et al., 1993a) . A set of 3 SNARE molecules assemble into a stable ternary complex, bringing the vesicle into apposition with a This article has not been copyedited and formatted. The final version may differ from this version.
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SNARE disassembly is regulated by N-ethyl-maleimide (NEM) sensitive factor (NSF).
NSF was discovered by Rothman and colleagues as an 85 kD protein that regulates vesicle fusion and is inhibited by NEM Malhotra et al., 1988; Rothman, 1994) .
Each of the 3 domains of NSF has a specific function. The N-terminal domain of NSF interacts indirectly with SNARE proteins via Soluble NSF Attachment Proteins (SNAP). The D1 domain of NSF hydrolyzes ATP and alters the conformation of the ternary SNARE complex. The D2 domain of NSF that regulates NSF oligomerization (Matveeva et al., 1997; May et al., 1999; Nagiec et al., 1995; Steel and Morgan, 1998; Tagaya et al., 1993; Whiteheart et al., 1994; Whiteheart et al., 2001 ). The critical role that NSF plays in exocytosis is emphasized by the Drosophila mutant comatose: this fly has a temperature sensitive mutation of the Drosophila NSF homolog (dNSF) which blocks synaptic transmission, resulting in paralysis at an elevated temperature (Pallanck et al., 1995) .
We recently showed that NSF regulates exocytosis of endothelial granules (Matsushita et al., 2003) . Furthermore, we discovered that nitric oxide (NO) regulates exocytosis by chemically modifying NSF (Matsushita et al., 2003) . Based on these observations, we hypothesized that inhibitors of NSF would block exocytosis. We now report the design and testing of a novel set of inhibitors that block exocytosis of endothelial granules by inhibiting NSF.
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Entry of TAT-NSF Peptides into Endothelial Cells
HAEC were incubated with 10 µM FITC labeled TAT-NSF peptides for 20 min, treated with 200 µg/ml of ethidium bromide to quench extracellular FITC, and fluorescence was measured in a Cytofluor 2300 fluorimeter (Millipore, Billerica, MA). FITC-positive cells were measured by FACS analysis.
ATPase Assay
The ATPase activity of NSF was measured by a coupled assay, in which ATP utilization is linked to the pyruvate kinase reaction, which generates pyruvate, which in turn is measured continuously with lactate dehydrogenase (Huang and Hackney, 1994) . Recombinant NSF (0.2 µg/µl) was pre-treated with buffer or TAT-NSF peptide for 10 min at 22˚C. ATPase reaction buffer (100 mM HEPES buffer, pH 7.0, 100 mM KCl, 10 mM MgCl 2 , 5 mM CaCl 2 , 10 mM ATP, 5 mM phosphoenol pyruvate, 50 U lactate dehydrogenase, and 50 U pyruvate kinase) was added to the mixture, followed by 10 µl of NADH (2 mg/ml in 1% sodium bicarbonate). The mixture was incubated for 10 min at 22˚C, and the absorbance was measured at 340 nm.
NSF Disassembly Assay
Analysis of the 7S and 20S complexes was performed according to previously published protocols (Sollner et al., 1993b) . The disassembly activity of NSF was measured by a coprecipitation assay (Pevsner et al., 1994) . Recombinant RGS-(His) 6 -NSF (0.1 µg/µl) was pretreated with buffer or TAT-NSF peptides for 10 min at 22˚C. Recombinant RGS-(His) 6 -α-SNAP (0.1 µg/µl), and SNARE polypeptides (0.1 µg/µl each of VAMP-3, SNAP-23, and GSTSyntaxin-4) were added, followed by either 5 mM ATP/10 mM MgCl 2 or 5 mM ATP-γS/10 mM MgCl 2 . This mixture of NSF and SNARE polypeptides was then incubated in binding buffer (4 This article has not been copyedited and formatted. The final version may differ from this version. 9 mM HEPES pH 7.4, 0.1M NaCl, 1 mM EDTA, 3.5 mM CaCl 2 , 3.5mM MgCl 2 , and 0.5% Nonidet P-40) and glutathione-sepharose beads for 1 h at 4˚C with rotation. The beads were washed with binding buffer 4 times, mixed with SDS-PAGE sample buffer, boiled for 3 min, and analyzed by immunoblotting.
Bleeding Times in Mice
Measurement of bleeding time in mice was performed as previously described (Weiss et al., 2002) . Mice were anesthetized with an intramuscular injection of ketamine and xylazine, and 5 mm of the distal tip of the tail was amputated. The tail was blotted with filter paper every 5 sec until the paper was no longer stained. If the animals bled for 20 min, the experiment was stopped, and the bleeding time was recorded as 20 min.
Bioavailability of TAT-NSF peptides in mice
Mice were injected intravenously with PBS, FITC alone, or 0.5 mg/kg FITC-TAT-NSF peptides. At various times after injection of peptide, the distal tip of the tail was amputated and blood collected. Fluorescence in the blood were measured by fluorimetry.
Statistics
The EC 50% for the TAT-NSF peptide inhibition of thrombin activated exocytosis from endothelial cells was calculated using the Marquardt algorithm.
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Results
Design of Peptide Inhibitors of NSF
We designed a set of fusion polypeptide inhibitors of NSF (Table) . The amino terminus of all fusion peptides is an 11 amino acid residue polypeptide fragment derived from the human immunodeficiency virus TAT domain (YGRKKRRQRRR). This domain can efficiently deliver peptides and polypeptides into cells via lipid raft macropinocytosis (Becker-Hapak et al., 2001; Schwarze et al., 1999; Vocero-Akbani et al., 2001; Vocero-Akbani et al., 2000; Wadia et al., 2004) . The amino terminal domain is followed by a linker domain consisting of GGG. The carboxy terminus of each fusion peptide is derived from unique domains of NSF. We selected NSF domains of 20 -25 amino acid residues from regions that we or others had shown by mutagenesis are critical for NSF function ( Table) . We predicted that these fragments of NSF would inhibit specific NSF activities, such as NSF ATPase activity, NSF disassembly of SNAREs, or NSF homohexamerization (Table) .
Using these principles of design, we synthesized a set of 5 fusion polypeptide inhibitors of NSF. The peptides are referred to as TAT-NSF fusion peptides, and are identified with a number corresponding to the amino terminal amino acid residue of NSF. For example, TAT-NSF222 is composed of 11 amino acids of the HIV TAT polypeptide (YGRKKRRQRRR) followed by 3 amino acids as a linker (GGG) followed by 23 amino acids of the NSF D1 domain, residues 222-243 (LDKEFNSIFRRAFASRVFPPE). The sequence of the entire fusion peptide designated TAT-NSF222 is YGRKKRRQRRR-GGG-LDKEFNSIFRRAFASRVFPPE.
We also designed a set of control TAT-NSF peptides. These peptides are composed of the intact TAT domain followed by a domain containing the TAT amino acid residues in a scrambled order. These peptides are referred to as TAT-NSFscr. For example, TAT-NSF57scr contains the TAT domain fused to the 22 amino acids of NSF from 57 -77 in a scrambled order. We then measured the effect of the active and control peptides upon NSF activities and exocytosis.
TAT-NSF Peptides Inhibit Weibel-Palade Body Exocytosis
We first explored the effect of TAT-NSF peptides upon endothelial exocytosis. We incubated HAEC for 20 min with increasing concentrations of each of the 5 TAT-NSF peptides:
TAT-NSF57, TAT-NSF-81, TAT-NSF222, TAT-NSF254, and TAT-NSF700. HAEC were then treated with thrombin, and the amount of vWF released into the media was measured by ELISA.
TAT-NSF peptides inhibit vWF release in a dose-dependent manner (Fig. 1A) . For TAT-NSF57 the EC 50% = 488 µM (R 2 = 0.999), for TAT-NSF81 the EC 50% = 1.9 µM (R 2 = 0.999), for TAT-NSF222 the EC 50% = 4.9 µM (R 2 = 0.996), for TAT-NSF254 the EC 50% = 107 µM (R 2 = 0.999), and for TAT-NSF700 the EC 50% = 0.2 µM (R 2 = 0.999). We then repeated these experiments using the control peptides. TAT-NSF scrambled peptides have no effect upon endothelial exocytosis (Fig. 1B) .
We examined the dose response of TAT-NSF81 and TAT-NSF700 in more detail. TAT-NSF81 inhibits thrombin induced exocytosis of endothelial cells in a dose-responsive manner (Fig. 1C) . TAT-NSF700 inhibits thrombin induced exocytosis of endothelial cells in a doseresponsive manner (Fig. 1C ).
We then explored the effect of TAT-NSF81 and TAT-NSF700 upon insulin release from a rat insulinoma cell line. Pancreatic islet cells release insulin by regulated exocytosis; we hypothesized that TAT-NSF polypeptides would inhibit insulin release. Accordingly, we treated the rat insulinoma cell line RIN-m5F with increasing amounts of TAT-NSF81 or TAT-NSF700.
This article has not been copyedited and formatted. The final version may differ from this version. The insulinoma cells were then exposed to low levels of glucose (2.8 mM) or high levels of glucose (28 mM) for 1 h, and the amount of insulin released into the media was measured by ELISA. Non-treated RIN-m5F cells release basal levels of insulin at low levels of glucose, and high glucose stimulates an additional release of insulin (Fig. 1D ). The TAT-NSF peptides inhibit glucose stimulation of insulin release (Fig. 1D ).
These data show that TAT-NSF peptides are inhibitors of endothelial exocytosis.
TAT-NSF Entry into Endothelial Cells
TAT peptides enter cells by the process of macropinocytosis (Wadia et al., 2004) . We 
Selected TAT-NSF Peptides Inhibit NSF ATPase Activity
We next explored the effect of TAT-NSF peptides upon NSF ATPase activity. The
ATPase activity of NSF is necessary for NSF to disassemble SNARE complexes and regulate exocytosis. We designed the TAT-NSF222 and TAT-NSF254 polypeptides to contain regions of NSF adjacent to or within NSF domains that mediate ATP hydrolysis (Dalal and Hanson, 2001 ).
We then tested the ability of these and other peptides to inhibit NSF ATPase activity.
Recombinant NSF was incubated with 10 µM of TAT-NSF peptides, and ATPase activity was measured by a coupled assay (Huang and Hackney, 1994) . Some of the TAT-NSF peptides have no effect upon NSF ATPase activity, and others have a more pronounced inhibition of NSF ATPase activity (Fig. 3A) . In particular, TAT-NSF81, TAT-NSF222, and TAT-NSF700 all inhibit NSF hydrolysis of ATP. The two peptides designed to inhibit NSF ATP hydrolysis are less effective than two other peptides which contain NSF domains far from the two regions known to bind and hydrolyze ATP (Fig. 3A) . We further defined TAT-NSF81
and TAT-NSF700 inhibition of NSF ATP hydrolysis. TAT-NSF81 and TAT-NSF700 inhibit NSF ATPase activity in a dose-responsive manner (Fig. 3B ).
TAT-NSF Peptides Inhibit NSF Disassembly Activity
We next explored the effect of TAT-NSF peptides upon NSF disassembly activity. In order for NSF to disassemble the SNARE complex, the N-terminal domain of NSF interacts with the SNARE complex via α-SNAP, and then NSF uses the chemical energy from ATP This article has not been copyedited and formatted. The final version may differ from this version. To measure the effects of TAT-NSF peptides upon NSF disassembly activity, we expressed in bacteria and purified recombinant (His) 6 -NSF, (His) 6 -α-SNAP, and 3 SNARE molecules found in endothelial cells: GST-syntaxin-4, VAMP-3, and SNAP-23 (Matsushita et al., 2003) . We then employed a co-precipitation assay to measure the interaction between NSF and SNAREs. In this assay, we pull down the SNARE syntaxin-4 and determine whether or not NSF precipitates along with syntaxin-4. As controls, we add ATP or ATP-γS. ATP-γS will lock NSF onto the SNARE complex; precipitation of syntaxin will also pull down NSF in the presence of ATP-γS. In contrast, ATP permits NSF to separate from the SNARE complex;
precipitation of syntaxin will not pull down NSF in the presence of ATP.
Recombinant (His) 6 -NSF was mixed with α-SNAP, GST-syntaxin, VAMP-3, and SNAP-23. ATP or ATP-γS was added, the mixture was precipitated with glutathione-sepharose beads, and precipitants were immunoblotted with antibody to the NSF (His) 6 tag. As expected, ATP permits NSF to release SNARE molecules, and NSF does not co-precipitate with SNAREs ( Fig.   4A , lane 1). Also as expected, ATP-γS locks NSF onto the SNARE complex, and NSF coprecipitates with SNAREs (Fig. 4A , lane 2).
We next added 1 µM individual TAT-NSF peptides to recombinant NSF, α-SNAP, and SNAREs, and then precipitated SNAREs and immunoblotted the precipitants with antibody to the NSF tag. All TAT-NSF peptides inhibit NSF disassociation from the SNARE complex (Fig.   4A ). TAT-NSF81 is particularly effective at blocking NSF disassembly activity. A doseresponse measurement shows that for TAT-NSF81 the EC 50% = 0.1 -1.0 µM (Fig. 4B) . The
This article has not been copyedited and formatted. The final version may differ from this version. control peptide TAT-NSF81scr has no effect (Fig. 4C) . A dose-response measurement shows that for TAT-NSF700 the EC 50% = 1.0 -10 µM (Fig. 4D) . The control peptide TATNSF700scr has no effect (Fig. 4E ).
Taken together, these data show that TAT-NSF peptides inhibit NSF disassembly activity.
TAT-NSF Peptides Prolong Bleeding Time in Vivo
In order to test whether or not TAT-NSF peptides have an effect upon exocytosis in vivo,
we measured the effect of TAT-NSF peptides upon the bleeding time of mice. Thrombosis depends in part upon endothelial exocytosis of vWF which interacts with the platelet gp Ib-IX-V receptor complex to mediate platelet adherence to the vessel wall (Ruggeri, 2002) . We hypothesized that TAT-NSF peptides would decrease endothelial exocytosis, decrease the endothelial release of vWF, decrease platelet adherence, and prolong the bleeding time.
We anesthetized mice and injected them intravenously with saline or TAT-NSF peptides.
After 45 min the distal 5 mm of tail was amputated and the bleeding time measured. (If the animals bled continuously for more than 20 min, the bleeding time was recorded as 20 min and the experiment was stopped.) Treatment with saline has no effect upon the bleeding time (Fig.   5A ). In contrast, treatment with the TAT-NSF peptides prolongs the bleeding time (Fig. 5A ). partial thromboplastin time (PTT), and the platelet count. TAT-NSF700 2.5 mg/kg has no effect upon the PT, PTT, or platelet count (data not shown).
We next measured the change over time in blood levels of FITC labeled TAT-NSF in mice. We injected PBS, FITC, or 0.5 mg/kg FITC-TAT-NSF peptides into mice, collected blood at various times, and measured the fluorescence of the blood. Blood from mice injected with PBS has minimal fluorescence (Fig. 5B, open triangle) . Fluorescence of blood from mice injected with FITC-TAT-NSF peptides decreases rapidly within the first 5 minutes, and then remains constant 10 -60 min after injection (Fig. 5B ).
These data show that TAT-NSF peptides prolong the bleeding time in vivo, and suggest that NSF is a novel target for treatment of thrombotic diseases.
Discussion
The major finding of this study is that novel fusion polypeptides can inhibit exocytosis.
Fusion polypeptides composed of a TAT protein transduction domain joined to an NSF domain can enter endothelial cells, inhibit specific NSF activities, and block exocytosis.
How do TAT-NSF peptides inhibit NSF?
We used rationale drug design to construct a set of polypeptides that would inhibit NSF.
The carboxy terminal region of each peptide contains a unique 22 amino acid residue domain of NSF. We selected each NSF domain based upon structure-function studies of NSF by us and others (Table) . NSF has at least 3 major functions: hydrolysis of ATP, disassembly of SNAREs, and homohexamerization.
We designed 2 TAT-NSF polypeptides to interfere with NSF hydrolysis of ATP. TAT-NSF222 and TAT-NSF254 contain regions of NSF adjacent to or within NSF domains that mediate ATP binding and hydrolysis (Dalal and Hanson, 2001 ). TAT-NSF222 contains an NSF domain extending from 222 -243 which is directly amino terminal to the Walker A motif of the D1 domain of NSF. TAT-NSF254 contains the NSF domain extending from residues 254-274 which includes the Walker A motif of the NSF D1 domain. Our ATPase assay shows that TAT-NSF222 does indeed inhibit NSF ATPase activity (Fig. 3) . However, TAT-NSF81 and TAT-NSF700 inhibit NSF ATPase activity even more than the two other peptides specifically targeted to the ATPase domains.
We designed 2 TAT-NSF polypeptides to block NSF disassembly of SNARE molecules.
TAT-NSF57 contains a region of NSF that interacts with the adaptor molecule α-SNAP that in turn interacts directly with SNAREs. TAT-NSF81 contains a Cys residue that mediates NO inhibition of NSF disassembly. TAT-NSF81 is more effective than TAT-NSF57 at inhibiting This article has not been copyedited and formatted. The final version may differ from this version. NSF disassembly of the SNARE complex (Fig. 4) . Since NSF hydrolysis of ATP is important for NSF disassembly of SNARE complexes, it is not surprising that the TAT-NSF polypeptides that inhibit NSF ATPase activity also inhibit NSF disassembly activity (Fig. 4) .
NSF forms homohexamers in a barrel shaped ring structure that is important for NSF function (Yu et al., 1998; Zhang et al., 2000) . We designed a peptide TAT-NSF700 that interferes with NSF interactions with other NSF molecules. However, we do not have a robust assay to detect NSF homohexamerization. Although TAT-NSF700 was the most potent inhibitor of exocytosis, the precise mechanism of its action is not yet known.
TAT-NSF entry into endothelial cells
TAT polypeptides enter cells by macropinocytosis (Wadia et al., 2004) . The composition of the TAT amino acid residues that affects the alpha-helical structure of the TAT domain influences TAT uptake into cells (Ho et al., 2001) . Furthermore, the composition of the NSF domain of the fusion polypeptides may also affect cellular uptake. Most of the TAT-NSF fusion polypeptides transduce similar percentages of endothelial cells (Fig. 2B) . However, the concentration of TAT-NSF peptides within cells after 20 min varies by approximately 20% ( Fig.   2A , black bars). For example, TAT-NSF57 and TAT-NSF700 achieve higher levels within endothelial cells compared to the other peptides ( Fig. 2A, black bars) . One possible explanation for this difference is that the amino acids in the NSF domain affect TAT-NSF peptide entry into cells. Another possibility is that more FITC molecules are attached to TAT-NSF700 and TAT-NSF57 than to the other TAT-NSF peptides ( Fig. 2A, white bars) . However, TAT-NSF81 has a higher fluorescence than the other peptides, yet has lower levels within cells. Thus FITC labeling alone cannot account for the entire difference in TAT-NSF levels within cells.
TAT-NSF peptides inhibit exocytosis
The TAT-NSF peptides inhibit exocytosis in endothelial cells. Each set of doseresponses was performed with a given lot of endothelial cells. However, the batch of endothelial cells used for one peptide differs from the cells used for another peptide. This may account for the variation in vWF release at baseline (Fig. 1) . Our data suggest that the mechanism by which the peptides inhibit exocytosis is by acting upon NSF, a protein which plays a critical role in exocytosis Malhotra et al., 1988; Rothman, 1994) . We also explored the effect of TAT-NSF peptides in insulinoma cells that release insulin by exocytosis. TAT-NSF peptides inhibit insulinoma release of insulin (Fig. 1D ). These data suggest that TAT-NSF peptides may be useful in the inhibition of exocytosis in a variety of cells.
How do TAT-NSF peptides prolong bleeding time?
Our novel set of NSF inhibitors prolongs bleeding times in mice (Fig. 5) , but the precise mechanisms are unknown. We hypothesize that TAT-NSF peptides act on endothelial cells, since TAT-NSF peptides cannot enter platelets (data not shown). We further hypothesize that TAT-NSF peptides then inhibit NSF and thereby block endothelial exocytosis of Weibel-Palade bodies from vascular endothelial cells, as supported by our data (Figs. 1-4) . Endothelial cells would then externalize less P-selectin and release less vWF. Less P-selectin on the surface of endothelial cells would decrease platelet adherence to the vessel wall mediated by the platelet surface protein P-selectin glycoprotein ligand-1 (PSGL-1) (Andre et al., 2000) . Less vWF released into the blood would decrease platelet adherence to the vessel wall mediated by the platelet gp Ib-IX-V receptor complex (Ruggeri, 2002) . The combined effects of decreased endothelial release of these mediators would in theory lead to decreased platelet adhesion to the vessel wall and thereby prolong the time to hemostasis (Fig. 5 ).
TAT-NSF concentrations in mouse blood
The blood levels of FITC-TAT-NSF decrease rapidly over the first 5 minutes after injection, and then do not change from 10 min after injection until at least 60 min after injection (Fig. 5B) . The initial blood concentration of FITC-TAT-NSF81 is higher than the other peptides (Fig. 5B) . The reason for this is unclear. FITC-TAT-NSF81 has higher levels of fluorescence than other FITC-TAT-NSF peptides in media alone ( Fig. 2A, white bars) . FITC-TAT-NSF81
has lower concentrations within cells ex vivo ( Fig. 2A, black bars) . Thus it is possible that FITC-TAT-NSF81has a higher basal level of fluorescence in vivo and also does not enter cells as rapidly in vivo, compared to the other FITC-TAT-NSF peptides, thus causing a higher initial level of fluorescence in vivo.
We also explored the effect of TAT-NSF peptides upon the bleeding time when administered intraperitoneally instead of intravenously. Although prior reports suggested that the protein transduction domain of TAT permits delivery of fusion polypeptides throughout the body, we found that TAT-NSF peptides have no effect upon bleeding time when administered intraperitoneally (data not shown). These results suggest that TAT-NSF fusion polypeptides This article has not been copyedited and formatted. The final version may differ from this version. Table. Design of TAT-NSF polypeptides. All TAT-NSF fusion polypeptides contain the TAT domain YGRKKRRQRRR followed by a linker GGG followed by a unique NSF domain. The NSF domains were selected based upon studies of the structure and function of NSF. 
